Research initiativeCore BCI
BrainGate
The academic consortium behind two decades of human intracortical BCI research.
- Location
- Providence, United States
- Founded
- 2004
- Class
- Core BCI
- Website
- braingate.org
- Sources last checked
- 3 Oct 2026
What they are building
A multi-institution research programme running the BrainGate2 feasibility study of intracortical neural interfaces for people with tetraplegia.
- Interface category
- Intracortical arrays
- Signal
- Action potentials and local field potentials
- Invasiveness
- Invasive
- Recording / stimulation
- Recording and stimulation
- Device
- Utah array (NeuroPort) — Rigid silicon microelectrode array, typically connected through a skull-mounted pedestal
- Channels
- 96 electrodes per array in most human studies
- Regulatory status
- Investigational for chronic BCI use
- Main use cases
- Communicate, Control, Move
- Works with
- Brown University / Providence VA Medical Center · Massachusetts General Hospital · Stanford University
Where they are clinically
Feasibility
Small early studies that test safety and whether the device can do what it is meant to.
Access today
Experimental human research
Demonstrated in a small number of research participants. Not an established treatment.
- Shown in people
- Two decades of peer-reviewed results: cursor control (2006), handwriting at 90 characters per minute (2021) and speech at 97.5% word accuracy over 8.4 months (2024).
- Still an aim
- It is a research programme and sells nothing. Its aim is evidence and methods that others build on.
- What stands in the way
- Research hardware: arrays wired through the skull, used with a study team's support.
On record here: 3 registered studies · 62 participants planned or enrolled · 7 peer-reviewed papers
This technology remains experimental and is not an established treatment. Access is limited to registered clinical studies.
Why this initiative matters
BrainGate is the field's reference programme. Its open publication record and released datasets set the benchmarks that commercial systems are now measured against, and its sites train many of the people who go on to build them. Its participants use arrays wired through the skull with a study team on hand, so the results show what is possible, not what a product delivers.
Key milestones
15 Aug 2024
Speech neuroprosthesis sustains 97.5% accuracy over 8.4 months in one participant.
12 May 2021
Handwriting decoded at 90 characters per minute.
May 2009
BrainGate2 feasibility study begins; it remains open across six US sites.
13 Jul 2006
First report of a person with tetraplegia controlling a cursor and devices with an intracortical array.
Clinical programmes
- Interfacing with neurotechnology to expand neural throughput
Academic study with Blackrock Neurotech as collaborator.
FeasibilityRecruiting
5 estimatedNCT07521930
- CRS-BMI
Bidirectional intracortical BCI: motor decoding with tactile feedback by microstimulation.
FeasibilityRecruiting
30 estimatedNCT01894802
- BrainGate2
The longest-running intracortical BCI study, open since 2009 across six US sites.
FeasibilityRecruiting
27 estimatedNCT00912041
Research
- 2025Inner speech in motor cortex and implications for speech neuroprostheses
Kunz EM et al. · Cell
- 2025An instantaneous voice-synthesis neuroprosthesis
Wairagkar M et al. · Nature
- 2025A high-performance brain–computer interface for finger decoding and quadcopter game control in an individual with paralysis
Willsey MS et al. · Nature Medicine
- 2024An Accurate and Rapidly Calibrating Speech Neuroprosthesis
Card NS et al. · New England Journal of Medicine
- 2023A high-performance speech neuroprosthesis
Willett FR et al. · Nature
- 2021A brain-computer interface that evokes tactile sensations improves robotic arm control
Flesher SN et al. · Science
- 2021High-performance brain-to-text communication via handwriting
Willett FR et al. · Nature
Leadership
Leigh R. Hochberg
Sponsor-investigator, BrainGate2
As publicly stated by the organisation. Not a complete list.
Competitive context
Sources
- 01
Hochberg LR et al. Nature 2006;442(7099):164–171 (opens in a new tab)
Peer reviewedNature13 Jul 2006Checked against source 3 Oct 2026
DOI 10.1038/nature04970
- 02
ClinicalTrials.gov NCT00912041 (opens in a new tab)
Clinical registryClinicalTrials.gov1 Jun 2026Checked against source 3 Oct 2026
Registry record last updated 2026-06-01.
- 03
Willett FR et al. Nature 2021;593(7858):249–254 (opens in a new tab)
Peer reviewedNature12 May 2021Checked against source 3 Oct 2026
DOI 10.1038/s41586-021-03506-2
- 04
Card NS et al. N Engl J Med 2024;391(7):609–618 (opens in a new tab)
Peer reviewedNew England Journal of Medicine15 Aug 2024Checked against source 3 Oct 2026
DOI 10.1056/NEJMoa2314132